Drug Trial Radar · NCT05468320
Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
Last checked: Nov 20, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Nov 21, 2022
Primary completion
Dec 26, 2024
Study completion Dec 26, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single group, treatment, Phase 3, open-label, single-arm study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy (IST) without firstline therapeutic plasma exchange (TPE) with primary endpoint of remission in male and female participants aged 18 to 80 years with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The anticipated study duration per participant without a recurrence while on therapy is maximum 24 weeks (ie, approximately 1 day for screening + maximum 12 weeks of treatment for the presenting episode + 12 weeks of follow-up). Participants will have daily assessments during hospitalization and weekly visits for assessments during ongoing treatment with caplacizumab and IST. There will be 3 outpatient visits for assessments during the follow-up period. There will be two additional follow-up visits for participants who do not have ADAMTS13 activity levels of ≥50% at the time of caplacizumab discontinuation.
Conditions
- Thrombotic Thrombocytopenic Purpura
Interventions
CaplacizumabDrug
Lyophilized powder for solution for injection.
CorticosteroidsDrug
Solution for injection or Tablet
anti-CD20 antibodyBiological
Solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study PeriodTime frame: From first dose of study treatment (Day 1) up to end of follow-up (up to approximately 24 weeks)
Locations
27 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama- Site Number : 8400011
Birmingham, Alabama
Johns Hopkins University- Site Number : 8400007
Baltimore, Maryland
Duke University Medical Center Site Number : 8400022
Durham, North Carolina
The Ohio State University Comprehensive Cancer Center - Site Number : 8400001
Columbus, Ohio
Investigational Site Number : 0560003
Yvoir, Belgium
Investigational Site Number : 1240001
Toronto, Ontario, Canada
Investigational Site Number : 2030001
Brno, Czechia
Investigational Site Number : 2030003
Prague, Czechia
Investigational Site Number : 2500002
Bois-Guillaume, France
Investigational Site Number : 2500005
Lille, France
Investigational Site Number : 2500003
Paris, France
Investigational Site Number : 2500001
Paris, France
Investigational Site Number : 2760006
Berlin, Germany
Investigational Site Number : 2760002
Cologne, Germany
Investigational Site Number : 2760001
Frankfurt am Main, Germany
Investigational Site Number : 2760004
Hanover, Germany
Investigational Site Number : 3800006
Genova, Italy
Investigational Site Number : 3800005
Verona, Italy
Investigational Site Number : 3800004
Vicenza, Italy
Investigational Site Number : 3800003
Avellino, Campania, Italy
Investigational Site Number : 3800001
Milan, Lombardy, Italy
Investigational Site Number : 3920003
Kurashiki-shi, Okayama-ken, Japan
Investigational Site Number : 3920001
Iruma-gun, Saitama, Japan
Investigational Site Number : 5280002
Amersfoort, Netherlands
Investigational Site Number : 7240001
Madrid / Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 8260002
Liverpool, United Kingdom
Investigational Site Number : 8260001
London, London, City of, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.